Pharmascience Inc. launches pms-ABIRATERONE for the Treatment of Metastatic Prostate Cancer

MONTREAL, January 15 2021 – Pharmascience Inc. is proud to launch pms-ABIRATERONE, a generic equivalent to ZYTIGA®, the Canadian reference product. Pms-ABIRATERONE is used in the treatment of metastatic prostate cancer (castration-resistant prostate cancer). Providing similar safety and efficacy profiles as the brand, pms-ABIRATERONE offers two doses, 250 mg and 500 mg at a lower cost. Along with this product, Pharmascience Inc. offers a brand-similar patient support program to ensure a smooth transition.

“In these turbulent times, Pharmascience continues to invest and innovate. The launch of pms-ABIRATERONE is yet another example of the company’s commitment to increase access to more affordable drugs in our fight against prostate cancer” says Al Moghaddam, Vice President and General Manager of Pharmascience Canada.



Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2020, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People and named as one of Montreal’s best employers, as part of the Canada’s Top 100 Employers project. Also, in 2020, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers.

Zytiga is a registered trademark of Johnson & Johnson

For product information, please contact Pharmascience’s Medical Information Department at 1-888-550-6060.

Published in

Product Launches